Surprisingly, two novel Eg5 inhibitors tested, namely compounds 2 and 41, evidenced a strong capability to significantly reduce adenocarcinoma cell viability, especially compound 2 which possesses an IC50 value lower than 3 μM, comparable with K858 IC50 value. Here, KIF11 is linked to adenocarcinoma.